Pharma Focus Asia

ALX Oncology Holdings Announces Clinical Trial Collaboration with Sanofi

Wednesday, April 26, 2023

ALX Oncology Holdings announced that it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate evorpacept in combination with SARCLISA (isatuximab-irfc) in patients with multiple myeloma.

This collaboration with Sanofi has the potential to advance a new combination therapy for patients with relapsed multiple myeloma who will benefit from novel effective treatment options. Moreover, collaboration expands robust clinical development pipeline with evorpacept, to establish a new and best-in-class foundational immunotherapy in both haematologic and solid tumours.

Under the terms of the agreement, Sanofi will conduct a Phase 1/2 study to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept in combination with SARCLISA and dexamethasone in patients with RRMM.

Part 1 will evaluate dosing of evorpacept in combination with standard doses of SARCLISA and dexamethasone to identify a recommended dose. Part 2 will investigate the efficacy and safety of this combination in an expanded population of patients with RRMM. ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024